Home  Index  News  Diabetes patients reminded of importance of preventative foot care

Diabetes patients reminded of importance of preventative foot care

Diabetes patients reminded of importance of preventative foot care

The European Medicines Agency (EMA) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin used for type 2 diabetes.

Patients taking these medicines are reminded to check their feet regularly and follow their doctor’s advice on routine preventative foot care. They should also tell their doctor if they notice any wounds or discoloration, or if their feet are tender or painful.

The review of SGLT2 inhibitors was prompted by an increase in lower limb amputations (mostly affecting the toes) in patients taking canagliflozin in two clinical trials, CANVAS and CANVAS-R. The studies, which are still ongoing, involved patients at high risk of heart problems and compared canagliflozin with placebo (a dummy treatment).

All patients with diabetes (especially those with poorly controlled diabetes and problems with the heart and blood vessels) are at higher risk of infection and ulcers (sores) which can lead to amputations. The mechanism by which canagliflozin may increase the risk of amputation is still unclear.

An increase in lower limb amputations has not been seen in studies with other medicines in the same class, dapagliflozin and empagliflozin. However, data available to date are limited and the risk may also apply to these other medicines.

Further data are expected from ongoing studies with canagliflozin, dapagliflozin and empagliflozin.

A warning of the potential increased risk of toe amputation will be included in the prescribing information for these medicines. For canagliflozin, the prescribing information will also list lower limb amputation as an uncommon side effect (occurring in between 1 and 10 patients in 1,000). Doctors may consider stopping treatment with canagliflozin if patients develop significant foot complications such as infection or skin ulcers

Date: 6/21/2017
Source :

In recent years Iran branch of Vitane was established with main focus on manufacturing biologics, special treatment and orphan drugs. The production site of the company will be opened in this year with some products which are entered to domestic market through contract manufacturing. CONTACT US »
With in headquarters in Germany , the company has entered into manufacturing alliances with leading pharmaceutical manufacturers in  Europe, Asia and Middle East.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to VITANE PHARMED Inc.